Angionesis inhibitors: New agents in cancer therapy

Drugs and Aging

Volumn 17, Issue 4, 2000, Pages 249-255

  Ryan, Charles J ^a   Wilding, George ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 4 DEDIMETHYLAMINOSANCYCLINE; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; CELL ADHESION MOLECULE; COMBRETASTATIN; CYTOKINE; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; INTEGRIN; INTERLEUKIN 12; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; MONOCLONAL ANTIBODY LM 609; SCLEROPROTEIN; SQUALAMINE; THALIDOMIDE; VASCULOTROPIN;

ANGIOGENESIS; CANCER THERAPY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION; CLINICAL TRIAL; NEOPLASM;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS; HUMANS; NEOPLASMS;

EID: 0033626436     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200017040-00001     Document Type: Review

References (38)

1. Tumor angiogenesis: Therapeutic applications
2. Tumor growth and neovascularization: An experimental model using rabbit cornea
3. Tumor angiogenesis
4. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry
5. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
6. Tumor angiogenesis: A New significant and independent prognostic indicator in early-stage breast carcinoma
7. β3 integrin expression in melanoma predicts subsequent metastasis
8. Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma
9. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
10. The integrin alpha V beta 3: Angiogenesis and apoptosis
11. Matrix metalloproteinase inhibitors: Applications in oncology
12. Determinants of tumor blood flow: A review
13. Cancer experts offer healthy dose of skepticism toward hype over antiangiogenesis agents
14. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
15. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
16. Endostatin induces endothelial cell apoptosis
17. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis
18. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
19. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis
20. Angiostatin induces and sustains dormancy of human primary tumors in mice
21. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma
22. Targeted anti-angiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3
23. Phase 1 and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies
24. Phase I study of BAY 12-9566: A matrix metalloproteinase inhibitor (MMPI)
25. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents
26. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(Chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice
27. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer
28. Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: Facing the challenge of a proper study design
29. Clinical studies with angiogenesis inhibitors: Biological rationale and challenges for their evaluation
30. Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers
31. Elevated levels of an angiogenic peptide, basic fibroblast growth factor in the urine of patients with a wide spectrum of cancers
32. Angiogenic activity of cervical carcinoma: Assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome
33. Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions
34. Detection of tumor angiogenesis in vivo by alphaV beta3-targeted magnetic resonance imaging
35. Drug development in prostate cancer